- Report
- July 2024
- 100 Pages
Global
From €2691EUR$3,000USD£2,367GBP
€3364EUR$3,750USD£2,959GBP
- Report
- May 2024
- 200 Pages
Global
From €3723EUR$4,150USD£3,274GBP
- Report
- February 2024
- 185 Pages
North America
From €3095EUR$3,450USD£2,722GBP
- Report
- October 2023
- 146 Pages
Africa, Middle East
From €3095EUR$3,450USD£2,722GBP
- Report
- October 2023
- 145 Pages
From €3095EUR$3,450USD£2,722GBP
- Report
- July 2023
- 198 Pages
Europe
From €3095EUR$3,450USD£2,722GBP
- Report
- June 2023
- 184 Pages
Asia Pacific
From €3095EUR$3,450USD£2,722GBP
- Report
- March 2023
- 185 Pages
Global
From €3992EUR$4,450USD£3,511GBP
- Report
- December 2021
- 209 Pages
Global
From €3992EUR$4,450USD£3,511GBP
- Report
- July 2023
- 140 Pages
Global
From €4440EUR$4,949USD£3,905GBP
- Report
- November 2025
- 50 Pages
Global
From €2377EUR$2,650USD£2,091GBP
- Book
- December 2018
- 277 Pages
From €116EUR$129USD£102GBP

Iodine-123 is a radioactive isotope of iodine used in Nuclear Medicine and Radiopharmacology. It is used in a variety of medical imaging procedures, such as thyroid scans, to diagnose and treat thyroid diseases. It is also used in the diagnosis of certain types of cancer, such as neuroendocrine tumors. Iodine-123 has a short half-life of 13.2 hours, making it ideal for use in Nuclear Medicine. It is produced in nuclear reactors and cyclotrons, and is available in a variety of formulations, including capsules, solutions, and injectables.
Companies in the Iodine-123 market include GE Healthcare, Mallinckrodt Pharmaceuticals, Jubilant DraxImage, and Bracco Diagnostics. Show Less Read more